Novo Nordisk invests in haemophilia with Denmark facility
pharmafile | May 5, 2015 | News story | Manufacturing and Production, Sales and Marketing | Novo Nordisk, diabetes, haemophilia, novoseven
Novo Nordisk is spending around $225 million on a new facility in Kalundborg, Denmark to produce active pharmaceutical ingredients for haemophilia products.
The firm says the move will create 100 new production and engineering jobs in the city where Novo Nordisk already employs just under 3,000 people.
“The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees,” says Henrik Wulff, executive VP, Product Supply, Novo Nordisk.
This new 7,500 m2 facility will now site within Novo’s huge 1,000,000 m2 manufacturing operations in the city. Established in 1969 Novo has made ongoing investments into the Kalundborg site since 1999 by creating more than 1,600 new jobs there.
Along with producing diabetes treatments which are the company’s speciality, this new unit will focus on haemophilia which is a bleeding disorder affecting one in 10,000 people. People with haemophilia have either decreased, defective or absent production of blood clotting protein.
The plant which is expected to be approved and fully operational by 2020, will make active pharmaceutical ingredients for its offering NovoSeven, and will work on future haemophilia products in tandem.
Just a few weeks back the firm announced more plant expansion, but this time in Russia, where it opened a new manufacturing facility to produce more of its diabetes offerings in the country.
It cut the tape on a plant in Kaluga for formulation and filling of modern insulin for the treatment of the disease. That production will cover both of its Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market, with the new facility being located in Technopark Grabtsevo in the Kaluga region.
Brett Wells
Related Content
Pfizer’s Beqvez approved by FDA for haemophilia B treatment
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Roche shares data on novel solution for continuous glucose monitoring
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …
